Gilead Sciences Inc’s shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
Silicon Valley Capital Partners
Managing Risk Inherent to Global Macroeconomics and Capital Market Opportunities